We are live on ! Find out more
GDTC icon

CytoMed Therapeutics
GDTC

3 hedge funds and large institutions have $12.2K invested in CytoMed Therapeutics in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.1% more ownership

Funds ownership: 0% → 0.1% (+0.1%)

0% more funds holding

Funds holding: 3 → 3 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

25% less capital invested

Capital invested by funds: $16.3K → $12.2K (-$4.1K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AIM
Axiom Investment Management
New York
+$7.3K

Top Sellers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
-$10.1K
2
UBS Group
UBS Group
Switzerland
-$1.4K

GDTC Hedge Fund Activity: Q2 2026 in Review

3 of the 8,320 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q2 2026, worth a combined $12.2K — down 25% from $16.3K a quarter earlier.

Fund positioning in GDTC was balanced in Q2 2026: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Axiom Investment Management, opening a new position worth an estimated $7.3K. The largest seller was XTX Topco, exiting entirely with an estimated $10.1K sold.

  • 3 institutional investors held CytoMed Therapeutics (GDTC) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $12.2K of CytoMed Therapeutics stock for Q2 2026, down 25% quarter-over-quarter.
  • 1 fund opened new CytoMed Therapeutics positions in Q2 2026 and 1 closed out, a net change of 0 holders.
  • The largest CytoMed Therapeutics buyer in Q2 2026 was Axiom Investment Management, an estimated $7.3K added.
  • The largest CytoMed Therapeutics seller in Q2 2026 was XTX Topco, an estimated $10.1K sold.

Based on aggregated 13F filings for Q2 2026.